Endocrine Abstracts

Background: Prostate cancer (PCa) is the fifth leading cause of cancer-related death worldwide. The main pharmacological strategy for this pathology is the blockade of the androgen receptor signalling pathway, commonly known as androgen-deprivation therapy. However, some of the patients does no longer respond to this hormonal therapy. Therefore, finding novel therapeutic strategies to tackle PCa, especially its most advanced phenotype [i.e., castration-resistant prostate cance...

Prostate cancer (PCa) is one of the most common endocrine-related cancers (ERCs) among men worldwide. The aggressiveness of this tumor pathology is highly influenced by different endocrine-related factors, highlighting the crucial role of androgens. Therefore, the main therapeutic approach for PCa patients is based on the pharmacological blockade of androgen-signaling. However, some patients become unresponsive and develop a highly lethal castration-resistant disease, pointing...